Real-world outcomes with systemic anticoagulation in inpatients with pancreatic cancer

Pancreatic cancer can induce a hypercoagulable state which may lead to clinically apparent thrombosis. The effects of anticoagulants in pancreatic cancer patients are unclear. A retrospective propensity score matched analysis of the U.S. Nationwide Inpatient Sample database found that among patients with pancreatic cancer, long-term systemic anticoagulant use was associated with decreased risks of some life-threatening events (sepsis, shock, acute kidney injury, in-hospital mortality) and shorter hospital stay.